Immunotherapy with NK cells: recent developments in gene modification open up new avenues

被引：32
作者：
Reindl, Lisa Marie [1 ,2 ]
Albinger, Nawid [1 ,2 ]
Bexte, Tobias [1 ,2 ]
Mueller, Stephan [1 ,2 ]
Hartmann, Jessica [3 ]
Ullrich, Evelyn [1 ,2 ,4 ]
机构：
[1] Goethe Univ Frankfurt, Childrens Hosp, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Expt Immunol, Frankfurt, Germany
[3] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany
[4] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany
来源：
ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期
关键词：
CAR; NK cells; NK-92; cells; cell therapy; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; MESSENGER-RNA; NK-92; CELLS; HEMATOPOIETIC-CELLS; CORD BLOOD; IN-VITRO; ADOPTIVE TRANSFER; VIVO EXPANSION;
D O I：
10.1080/2162402X.2020.1777651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
引用
收藏
页数：12
相关论文
共 120 条
[111]   Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 [J].
Tonn, T ;
Becker, S ;
Esser, R ;
Schwabe, D ;
Seifried, E .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (04) :535-544
[112]   Rapid and highly efficient gene transfer into natural killer cells by nucleofection [J].
Trompeter, HI ;
Weinhold, S ;
Thiel, C ;
Wernet, P ;
Uhrberg, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 274 (1-2) :245-256
[113]   New prospects on the NKG2D/NKG2DL system for oncology [J].
Ullrich, Evelyn ;
Koch, Joachim ;
Cerwenka, Adelheid ;
Steinle, Alexander .
ONCOIMMUNOLOGY, 2013, 2 (10)
[114]   Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells [J].
Wang, Jiao ;
Lupo, Kyle B. ;
Chambers, Andrea M. ;
Matosevic, Sandro .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[115]  
WANG M, 2008, BMC GENOMICS, V9, DOI DOI 10.1186/1471-2164-9- 225
[116]   A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy [J].
Williams, Brent A. ;
Law, Arjun Datt ;
Routy, Bertrand ;
denHollander, Neal ;
Gupta, Vikas ;
Wang, Xing-Hua ;
Chaboureau, Amelie ;
Viswanathan, Sowmya ;
Keating, Armand .
ONCOTARGET, 2017, 8 (51) :89256-89268
[117]   Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. [J].
Wu, Lei ;
Adams, Mary ;
Carter, Troy ;
Chen, Roger ;
Muller, George ;
Stirling, David ;
Schafer, Peter ;
Bartlett, J. Blake .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4650-4657
[118]   Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients [J].
Xiao, Lin ;
Cen, Dongzhi ;
Gan, Haining ;
Sung, Yan ;
Huang, Nanqi ;
Xiong, Hanzhen ;
Jin, Qiongmei ;
Su, Liqun ;
Liu, Xuejuan ;
Wang, Kejian ;
Yan, Guangrong ;
Dong, Tianfa ;
Wu, Shangbiao ;
Zhou, Pengzhi ;
Zhang, Jinshan ;
Liang, Weixiang ;
Ren, Junlan ;
Teng, Yaoshu ;
Chen, Can ;
Xu, Xue Hu .
MOLECULAR THERAPY, 2019, 27 (06) :1114-1125
[119]  
You FT, 2019, AM J CANCER RES, V9, P64
[120]  
Zhang R, 2004, ONCOL REP, V11, P1097
3456789101112